Practical Takeaways for Patients, Providers, and Payers

The final segment consolidates major insights and tailors them to three key audiences: patients, providers, and payers.

For patients, Dr. Rotow emphasizes the importance of self-advocacy, particularly ensuring that comprehensive molecular profiling has been performed. Because actionable biomarkers evolve over time, even patients previously treated with immunotherapy should revisit their genomic testing to confirm no opportunities were missed. Patients can directly influence their care by asking these questions.

For providers, the message is similar but more technical: perform broad, multimodaltesting that includes next-generation sequencing, RNA sequencing, and immunohistochemistry to avoid missing low-frequency alterations like BRAF...